Medical
-
Marinomed Biotech said that it has submitted an MAA via the decentralized marketing authorization procedure for a xylometazoline decongestant nasal spray formulated with the company’s Carragelose red algae extract. The company currently markets a range… Read more . . .
-
Destiny Pharma and SporeGen have agreed to co-develop a bacillus nasal spray as a prophylactic for prevention of COVID-19, with much of the project cost covered by an £800,000 grant from Innovate UK. Pan Group… Read more . . .
-
Verona Pharma has initiated a study of its ensifentrine MDI in patients hospitalized with COVID-19 at the University of Alabama Birmingham (UAB), the company said. The company has been developing the MDI formulation for the… Read more . . .
-
US biotech Diomics Corporation has announced plans to develop a prophylactic nasal spray against COVID-19 using antibodies licensed from Active Motif. According to the company, the Dioguard nasal spray, currently in in vitro testing, uses… Read more . . .
-
According to Aridis Pharmaceuticals, the FDA has agreed to allow a Phase 2a trial of the company’s AR-501 nebulized formulation of gallium citrate for the treatment of lung infections in cystic fibrosis patients to skip… Read more . . .
-
Auris Medical said that the first part of the Phase 2 TRAVERS study of its AM-125 intranasal betahistine for the treatment of vertigo has demonstrated a dose dependent improvement in balance up to 2.4 times… Read more . . .
-
Savara has discontinued development of Molgradex inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection and will not restart the Phase 2a ENCORE study of Molgradex for NTM… Read more . . .
-
MediciNova said that it has tested a number of intranasal SARS-CoV-2 vaccine prototypes using a viral vector technology platform from Mie University and BioComo and has identified several candidates that it plans to advance. BioComo’s… Read more . . .
-
Partner Therapeutics (PTx) has announced the initiation of the iLeukPulm Phase 2 trial of an inhaled formulation of its Leukine sargramostim in hospitalized COVID-19 patients in respiratory distress. Partner recently signed a $35 million contract… Read more . . .
-
Altimmune has announced that a preclinical study of its intranasal COVID-19 vaccine candidate AdCOVID has demonstrated a strong immune response in the lungs of mice, particularly in the stimulation of CD8+ T cells. In July… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan